Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients

American Journal of the Medical Sciences

Volumn 339, Issue 5, 2010, Pages 433-439

  Doi, Masayuki ^a   Miyoshi, Toru ^b   Hirohata, Satoshi ^b   Kamikawa, Shigeshi ^b   Usui, Shinichi ^b   Kaji, Youko ^c   Sakane, Kosuke ^c   Ogawa, Hiroko ^b   Ninomiya, Yoshifumi ^b   Kusachi, Shozo ^b  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Sumitomo Besshi Hospital   (Japan)

Author keywords

Angiotensin receptor blocker; Calcium channelblocker; Combination therapy; Hypertension; Wave reflection

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZELNIDIPINE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; LOSARTAN; N(G),N(G) DIMETHYLARGININE; OLMESARTAN; STATIN; SULFONYLUREA; TELMISARTAN; TRICHLORMETHIAZIDE; VALSARTAN;

ADULT; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; FEMALE; GLUCOSE METABOLISM; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID ANALYSIS; MALE; MEAN ARTERIAL PRESSURE; PROTEIN BLOOD LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 77952277125     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d658c4     Document Type: Article

References (38)

1. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3.
2. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol 2006;47:636-42.
3. Raicu M, Pojoga L, Simionescu N, et al. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study. J Submicrosc Cytol Pathol 1997;29:317-28.
4. Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995; 9 (suppl 3) : 509-23.
5. Jinno T, Iwai M, Li Z, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004;43:263-9.
6. Suzuki J, Iwai M, Li Z, et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005;23:1383-9.
7. Ogawa S, Mori T, Nako K, et al. Combination therapy with reninangiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008;31:1147-55.
8. Murgo JP, Westerhof N, Giolma JP, et al. Aortic input impedance in normal man: relationship to pressure wave forms. Circulation 1980;62:105-16.
9. Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension 2004;43:1239-45.
10. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003;23:554-66.
11. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
12. Guerin AP, Pannier B, Metivier F, et al. Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:635-41.
13. Doi M, Miyoshi T, Hirohata S, et al. Increased augmentation index of the radial pressure waveform in patients with paroxysmal atrial fibrillation. Cardiology 2009;113:138-45.
14. Shinohata R, Nakatsu T, Yuki Y, et al. Association of augmentation index of radial pressure wave form with diurnal variation pattern of blood pressure in untreated patients with essential hypertension. J Hypertens 2008;26:535-43.
15. Kohara K, Tabara Y, Oshiumi A, et al. Radial augmentation index: a useful and easily obtainable parameter for vascular aging. Am J Hypertens 2005;18:11S-14S.
16. Miyoshi T, Hirohata S, Uesugi T, et al. Relationship between activin A level and infarct size in patients with acute myocardial infarction undergoing successful primary coronary intervention. Clin Chim Acta 2009;401:3-7.
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
19. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
20. Matsui T, Yamagishi S, Nakamura K, et al. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epitheliumderived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005;31:215-9.
21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-07.
22. MacAllister RJ, Fickling SA, Whitley GS, et al. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-8.
23. Rawal N, Rajpurohit R, Lischwe MA, et al. Structural specificity of substrate for S-adenosylmethionine: protein arginine N-methyltransferases. Biochim Biophys Acta 1995;1248:11-8.
24. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-23.
25. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.
26. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
27. Weber T, Maas R, Auer J, et al. Arterial wave reflections and determinants of endothelial function a hypothesis based on peripheral mode of action. Am J Hypertens 2007;20:256-62.
28. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-9.
29. Soveri I, Lind L, Wikstrom B, et al. Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels. Nephron Clin Pract 2007; 106: c180-6.
30. Ito A, Egashira K, Narishige T, et al. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001;65:775-8.
31. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75.
32. Matsubara M, Akizuki O, Ikeda J, et al. Benidipine, an antihypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 2008;580:201-13.
33. Hirayama A, Ueda A, Oteki T, et al. In vivo imaging of renal redox status during azelnidipine treatment. Hypertens Res 2008;31:1643-50.
34. Jiang XJ, O'Rourke MF, Zhang YQ, et al. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007;25:1095-9.
35. Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23.
36. Meeks WM. Pathophysiology of hypertension in the elderly. Semin Nephrol 2002;22:65-70.
37. Kielstein JT, Bode-Boger SM, Frolich JC, et al. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003;107:1891-5.
38. Takazawa K, Kobayashi H, Shindo N, et al. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007;30:219-28.